Re: Freedman et al: Low- and very low-dose bevacizumab for retinopathy of prematurity: reactivations, additional treatments, and 12-month outcomes (Ophthalmology. 2022;129:1120-1128)

Ophthalmology. 2023 May;130(5):e18. doi: 10.1016/j.ophtha.2022.12.016. Epub 2023 Jan 24.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Bevacizumab / therapeutic use
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Intravitreal Injections
  • Retinopathy of Prematurity* / drug therapy

Substances

  • Bevacizumab
  • Angiogenesis Inhibitors